Rashmee Patil
About
In The Last Decade
Rashmee Patil
18 papers receiving 681 citations
Hit Papers
Peers
Comparison fields: 5 of 71
- Epidemiology 477
- Molecular Biology 223
- Endocrinology, Diabetes and Metabolism 218
- Hepatology 180
- Surgery 92
Countries citing papers authored by Rashmee Patil
This map shows the geographic impact of Rashmee Patil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rashmee Patil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rashmee Patil more than expected).
Fields of papers citing papers by Rashmee Patil
This network shows the impact of papers produced by Rashmee Patil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rashmee Patil. The network helps show where Rashmee Patil may publish in the future.
Co-authorship network of co-authors of Rashmee Patil
This figure shows the co-authorship network connecting the top 25 collaborators of Rashmee Patil. A scholar is included among the top collaborators of Rashmee Patil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rashmee Patil. Rashmee Patil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | Efruxifermin in Compensated Liver Cirrhosis Caused by MASH breakdown → | 19 |
| 3 | 72 | |
| 4 | NAFLD‐related hepatocellular carcinoma: The growing challenge breakdown → | 150 |
| 5 | 0 | |
| 6 | 18 | |
| 7 | Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial breakdown → | 255 |
| 8 | 5 | |
| 9 | 101 | |
| 10 | 2 | |
| 11 | 1 | |
| 12 | 4 | |
| 13 | 13 | |
| 14 | 24 | |
| 15 | 7 | |
| 16 | 5 | |
| 17 | 14 | |
| 18 | 2 | |
| 19 | 1 | |
| 20 | Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. | 13 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.